https://www.selleckchem.com/products/dwiz-2.html
070±0.16mg/dL vs. 0.107±0.13mg/dL, p=0.001). With regards to the primary endpoint, a significantly higher change in serum creatinine from baseline to 48-72h was observed in the sham group compared to the RIPC group (0.023±0.2μmol/L vs-0.064±0.1μmol/L, p0.001). RIPC as an alternative to standard therapy, improved serum creatinine levels after contrast administration in patients at risk of CIN. However, present data indicate that RIPC might have beneficial effects in patients with a moderate or high risk of CIN. RIPC as an alternative
Like
Comment
Share
